Thursday, December 1, 2011
A Memorial Sloan-Kettering Cancer Center team has
honed a protocol for producing large quantities of human dopaminergic neurons
that could be used therapeutically by grafting them into patients with
Parkinson's disease or as a platform for drug screening for the disease.1
But scaling up the protocol remains a challenge, and therapeutic applications
face major regulatory issues due to potential safety concerns.
L. SciBX 4(46);
doi:10.1038/scibx.2011.1285 Published online Dec. 1, 2011
1. Kriks, S. et al.
Nature; published online Nov. 6, 2011; doi:10.1038/nature10648 Contact:
Lorenz Studer, Memorial Sloan-Kettering Cancer Center, New York, N.Y. e-mail: firstname.lastname@example.org
2. Chambers, S.M. et
al. Nat. Biotechnol. 27, 275-280 (2009)
3. Hedlund, E. et al.
Stem Cells 26,1526-1536 (2008)
AND INSTITUTIONS MENTIONED
BrainStorm Cell Therapeutics Inc. (OTCQB:BCLI), New York, N.Y.
Cellular Dynamics International Inc., Madison, Wis.
Geron Corp. (NASDAQ:GERN), Menlo Park, Calif.
Harvard Medical School, Boston, Mass.
International Stem Cell Corp. (OTCBB:ISCO), Carlsbad, Calif.
Memorial Sloan-Kettering Cancer Center, New York, N.Y.
NeuroGeneration Inc., Los Angeles, Calif.
University of Colorado Denver School of Medicine, Aurora, Colo.